- Home
- XNCR vs HTFL Comparison
XNCR vs HTFL Comparison
Compare XNCR & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XNCR | HTFL |
|---|---|---|
| Founded | 1997 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | 2013 | 2025 |
Fundamental Metrics
Financial Performance| Metric | XNCR | HTFL |
|---|---|---|
| Price | $29.30 | $49.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $22.33 | ★ $38.20 |
| AVG Volume (30 Days) | 1.1M | ★ 1.9M |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 65.36 | ★ 82.37 |
| EPS | N/A | ★ N/A |
| Revenue | $125,576,000.00 | ★ $176,034,000.00 |
| Revenue This Year | N/A | $27.66 |
| Revenue Next Year | $4.80 | $23.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 13.65 | ★ 39.92 |
| 52 Week Low | $7.80 | $20.13 |
| 52 Week High | $29.42 | $50.85 |
Technical Indicators
Market Signals| Indicator | XNCR | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 83.18 | 88.97 |
| Support Level | $11.20 | $24.59 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.44 | 2.48 |
| MACD | 0.58 | 2.05 |
| Stochastic Oscillator | 100.00 | 97.88 |
Price Performance
Historical ComparisonAbout XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
About HTFL Heartflow Inc.
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.